LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing ...
Agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir (CAB LA) for treatment in 133 countries Builds on the voluntary licence for CAB LA for HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback